David Hochman
Chairman & CEO
Orchestra BioMed
Chairman & CEO
Orchestra BioMed
September 19, 2026 | 09:40 AM (EDT) - 10:25 AM (EDT)
David Hochman
David Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. From 2006 to 2019, he was Managing Partner of Orchestra Medical Ventures, a medical technology venture capital firm. He also served as President of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra. David has over 23 years of healthcare entrepreneurial, venture capital and investment banking experience. He is also Chairman of the Board of Motus GI (NASDAQ: MOTS). He was a co-founder and served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage biopharmaceutical company, from 2013 to 2020. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. He currently serves as President of the Board of the Mollie Parnis Livingston Foundation. He has a B.A. degree with honors from the University of Michigan.